28
Jul

Early this year Zealand Pharma and Boehringer Ingelheim agreed to start over on their three-year-old collaboration to develop a GLP-1 diabetes drug after they decided to part ways on a lead program. Now the Danish biotech will ramp up a second preclinical peptide program with the German pharma company aimed at cardio-metabolic diseases.

…read more

Source: Zealand inks a $402M cardio-metabolic peptide program with Boehringer

    

0 No comments